| Identification | Back Directory | [Name]
Pramipexole | [CAS]
191217-81-9 | [Synonyms]
Mirapex
Pra-API
Pramipexole
Unii-3D867np06j
PPX dihydrochloride
Pramipexole HCl hydrate
Mirapex,Sifrol,Mirapexin
Pramipexole 2HCl Hydrate
PraMipexole dihydrochloride Monohy
PraMipexole dihydrochloride hydrate
Pramipexole (hydrochloride hydrate)
Pramipexole Dihydrochloride Monohyd
Pramipexole dihydrochloride 1-hydrate
Pramipexole for system suitability CRS
PraMipexole dihydrochloride Monohyrate
Pramipexole dihydrochloride monohydrate
PramipexoleDihydrochlorideMonohydrate>
Pramipexole dihydrochloride monohydrate CRS
99.9%, Pramipexole Dihydrochloride Monohydrate?
Pramipexole Dihydrochloride Monohydrate (200 mg)
Pramipexole hydrochloride（Dihydrochloride monohydrate）
Pramipexole Dihydrochloride Monohydrate
DISCONTINUED, offer P700755 or P700750
(6S)-N'-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrate dihydrochloride
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate
(S)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol2HClH2Otetrahydrobenzothiazol
2,6-BenzothiazolediaMine,4,5,6,7-tetrahydro-N6-propyl-,hydrochloride,hydrate(1:2:1),(6S)-
(6S)- 4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine,hydrochloride,hydrate (1:2:1)
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole
-2,6-diamine hydrate dihydrochloride
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, monohydrate, (6S)- | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C10H21Cl2N3OS | [MDL Number]
MFCD00876894 | [MOL File]
191217-81-9.mol | [Molecular Weight]
302.26 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
290 °C(dec.) | [storage temp. ]
2-8°C | [solubility ]
Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. | [form ]
neat | [color ]
White to Almost white | [Merck ]
14,7705 | [BCS Class]
1 | [InChI]
InChI=1/C10H17N3S.ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);1H;1H2/t7-;;/s3 | [InChIKey]
ZTZQAWQFTIVKMU-DCFBZVEJNA-N | [SMILES]
NC1SC2C[C@@H](NCCC)CCC=2N=1.Cl.O |&1:5,r| |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Uses]
Antidepressant; antiparkinsonian; antischizophrenic; dopamine
agonist. | [Definition]
ChEBI: A hydrate that is the monohydrate of the dihydrochloride salt of pramiprexole. | [Brand name]
Mirapex (Boehringer Ingelheim). | [Description]
Pramipexole dihydrochloride monohydrate is an activator of D2DR, D3DR and D4DR. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways. | [General Description]
Pramipexole Dihydrochloride is a non-ergot dopamine agonist widely used for the treatment of early and advanced Parkinson′s disease (PD). It is also used to treat restless legs syndrome.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. | [Clinical Use]
Parkinson’s disease
Symptomatic treatment of restless legs | [Side effects]
Dizziness, lightheadedness, or fainting, especially when standing up suddenly from a sitting/lying position.
drowsiness.
nausea.
seeing, hearing, or feeling things that are not there.
trouble sleeping.
twitching, twisting, or other unusual body movements.
unusual tiredness or weakness. | [Drug interactions]
Potentially hazardous interactions with other drugs
Avoid concomitant use with antipsychotics. | [Metabolism]
Pramipexole undergoes <10% metabolism to inactive
metabolites.
More than 90% of a dose is excreted via renal tubular
secretion unchanged into the urine. |
|
|